secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001437749-26-008611
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing
--------------------------------------------------------------------------------

- FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.
- FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.
- Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.
- Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.
- Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/0001437749-26-008611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/crvo20260317_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer